Client: A Gulf-based healthcare services venture targeting Chinese cell and gene therapy companies. Service line: Strategic Growth Solutions.

At a glance

  • ~30 companies scored on a weighted prioritisation matrix

  • 23-page strategy blueprint plus execution toolkit

  • English and Mandarin outreach, including WeChat scripts

  • A 10-week implementation programme with CRM stages

The question

A Gulf-based healthcare services venture wanted to become the regional entry partner for Chinese cell and gene therapy companies. Which companies had a real reason to talk now, and what would make the first conversation credible?

The situation

The venture had a broad, unprioritised list and outreach messaging built on generic claims of an 'untapped market'. Its regulatory language mixed up authorities across the region, a credibility risk with sophisticated biotech teams who know their own regulators' review clocks precisely.

Our approach

  • Started by pressure-testing the target profile, value proposition and service boundaries with the founding team, so outreach would promise only what the venture could deliver.

  • Expanded the prospect universe to around 30 therapeutic companies and scored each on evidence of regional intent: Gulf partnerships, Saudi orphan-drug designations, international trials and footprint, and funding strength.

  • Desk research across company disclosures, regulator publications and industry sources, distinguishing verified facts from speculation.

  • Regulatory benchmarking of published review timelines and pathways in China, the UAE and Saudi Arabia.

  • Channel research into Chinese professional media, events and platforms, with labelled estimates where public data stopped.

What we delivered

  • A 23-page strategy blueprint with a scored prioritisation matrix, funding and footprint context, and public contact routes.

  • Corrected regulatory positioning: the federal regulator in the UAE versus emirate-level health authorities, published service times rather than promised dates, and pathway selection in Saudi Arabia.

  • A thought-leader and event map: policy and industry voices for webinars, and the partnering forums where decision makers meet, with audience metrics and contact routes.

  • An outreach system: formal English and culturally adapted Mandarin emails, a Day 1/7/14 follow-up sequence, WeChat scripts, an event plan and a sponsored-content plan.

  • A 10-week implementation programme, launch checklist, CRM stage definitions and lead-qualification fields.

  • Hands-on onboarding to the blueprint and toolkit, leaving the team able to run the campaign independently.

What we found

  • A small group of companies had already moved beyond interest to action, through Gulf partnerships, regional offices or Saudi orphan designations; they, not the long list, deserved first effort.

  • Accuracy is the entry ticket: one wrong regulatory claim ends the conversation with an informed biotech team.

  • The regional opportunity is best framed through concrete ecosystem developments, not market-size superlatives.

What changed

The venture replaced a broad, generic campaign with a focused, evidence-led one: a ranked shortlist with a reason to talk now, regulatory messaging that survives an informed first meeting, and a bilingual outreach system ready to run.

What it shows

In specialist markets, precision is persuasion. The partner that gets the pathway right in the first email earns the second meeting.

Facing a similar question? Talk to us about it.

Case notes are anonymised. Client names, figures and identifying details are withheld or generalised.